EXACT SCIENCES REPORTS NET LOSS OF $14.5 MILLION FOR 2005.

EXACT Sciences Corporation (NASDAQ: EXAS), Marlborough, Mass., has announced its financial results for the fourth quarter and year ended December 31, 2005.

For the quarter ended December 31, 2005, revenues totaled $1.2 million versus revenues of $1.3 million for the quarter ended December 31, 2004. For the twelve months ended December 31, 2005, revenues totaled $4.3 million, versus $4.9 million for the same time period of 2004. These revenues mainly reflect the amortization of up-front license fee payments from Laboratory Corporation of America(R) Holdings (LabCorp(R)) and, to a lesser extent, royalties on LabCorp's sales of PreGen-Plus(TM) (LabCorp's colon cancer screening testing service), and sales of Effipure(TM) units to LabCorp.

The decrease in revenue for the year ended December 31, 2005 as compared to the same period of the prior year was primarily the result of a one-time, non-cash reduction in revenue of $0.6 million recorded in June 2005 in connection with the June 2005 extension of the expiration date of a warrant originally issued to LabCorp in June 2002. Net loss for the quarter ended December 31, 2005 totaled $2.7 million, or $0.10 per share, compared to a net loss of $4.6 million, or $0.17 per share, for the quarter ended December 31, 2004. Net loss for the twelve months ended December 31, 2005 was $14.5 million, or $0.55 per share, versus a net loss of $18.5 million, or $0.73 per share for the twelve months ended December 31, 2004.

The reduction in the net loss for the quarter and year ended December 31, 2005 versus the same periods of the prior year was primarily due to reductions in applied research and administrative expenses. Actions taken by the company during 2005 to reduce its operating costs and cash burn included focusing research efforts on improving the performance aspects of the company's technology through smaller, less expensive studies leveraging results of the company's prior studies, including its large-scale multi-center study.

For the year ended December 31, 2005, over 4,000 PreGen-Plus tests were accessioned by LabCorp. As of December 31, 2005, the company had approximately $34.1 million in cash, cash equivalents and marketable securities.

About EXACT Sciences Corporation

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies are currently being offered in a commercial testing service, "PreGen-Plus(TM)," developed by Laboratory Corporation of America Holdings (LabCorp). PreGen-Plus is used for screening for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies will help enable detection of colorectal cancer so that more people can be effectively treated. Founded in 1995, EXACT Sciences is based in Marlborough, Mass.

This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the company's Annual Report on Form 10-K for the year ended December 31, 2005, which will be filed in March 2006.

For more information on EXACT Sciences and PreGen-Plus visit http://www.exactsciences.com and http://www.pregenplus.com or call 508/683-1275.